News Focus
News Focus
Followers 0
Posts 3251
Boards Moderated 0
Alias Born 04/21/2025

Re: improving post# 776815

Saturday, 07/19/2025 11:50:15 AM

Saturday, July 19, 2025 11:50:15 AM

Post# of 826027
For that one positive JAMA (Look at the long list of conflicts of interest in that puff piece) , there are multiple other peer reviewed pieces totally discrediting the phase 3 trial and DCVAX
Learn how to read more than ONE thing.
Here are just a couple.

https://www.sciencedirect.com/science/article/pii/S0035378723009190?via%3Dihub

https://academic.oup.com/neuro-oncology/article/25/4/631/6958519?login=false


"To conclude, stringently designed and executed prospective randomized clinical trials remain the gold standard for evaluation of efficacy of novel treatments. Control of known, but also unknown, confounders are crucial in clinical trials, and the present analyses of the DCVax-L trial offer neither"



"9. Conclusion
This dendritic vaccine trial has several limitations. These limitations include changing the primary endpoint (OS instead of PFS), creating a new study population (recurrent glioblastoma), conducting unplanned analyses, using external controls in a design originally intended to be randomized, all changes occurring years after the trial finished enrollment. The selected external controls likely included patients with less favorable outcomes, which opposes the “fit-for-purpose” criteria usually applied in selecting external controls. Therefore, the purported survival benefit from the vaccine is unreliable."

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News